Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenvatinib for Anaplastic Thyroid Cancer.
Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus CE, Takahashi S. Tahara M, et al. Among authors: sasaki t. Front Oncol. 2017 Mar 1;7:25. doi: 10.3389/fonc.2017.00025. eCollection 2017. Front Oncol. 2017. PMID: 28299283 Free PMC article.
A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Fukuda N, Sasaki T, Suzuki T, Ikezawa H, Dutcus CE, Tahara M. Takahashi S, et al. Among authors: sasaki t. Future Oncol. 2019 Mar;15(7):717-726. doi: 10.2217/fon-2018-0557. Epub 2019 Jan 14. Future Oncol. 2019. PMID: 30638399 Free article. Clinical Trial.
A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.
Nakamichi S, Nokihara H, Yamamoto N, Yamada Y, Honda K, Tamura Y, Wakui H, Sasaki T, Yusa W, Fujino K, Tamura T. Nakamichi S, et al. Among authors: sasaki t. Cancer Chemother Pharmacol. 2015 Dec;76(6):1153-61. doi: 10.1007/s00280-015-2899-0. Epub 2015 Nov 3. Cancer Chemother Pharmacol. 2015. PMID: 26530955 Free PMC article. Clinical Trial.
Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, Boku N, Onozawa Y, Hsu CP, Gorski KS, Friberg G, Kawaguchi T, Sasaki T. Doi T, et al. Among authors: sasaki t. Cancer Chemother Pharmacol. 2011 Sep;68(3):733-41. doi: 10.1007/s00280-010-1544-1. Epub 2010 Dec 16. Cancer Chemother Pharmacol. 2011. PMID: 21161528 Clinical Trial.
PI5P4K inhibitors: promising opportunities and challenges.
Takeuchi K, Nagase L, Kageyama S, Kanoh H, Oshima M, Ogawa-Iio A, Ikeda Y, Fujii Y, Kondo S, Osaka N, Masuda T, Ishihara T, Nakamura Y, Hirota Y, Sasaki T, Senda T, Sasaki AT. Takeuchi K, et al. Among authors: sasaki t. FEBS J. 2025 Jan 19. doi: 10.1111/febs.17393. Online ahead of print. FEBS J. 2025. PMID: 39828902 Review.
Real-world clinical practice of current periprocedural anticoagulation management in catheter ablation of atrial fibrillation: Data from a large prospective ablation registry.
Taomoto Y, Miyazaki S, Nagata Y, Nitta J, Inaba O, Shirai Y, Tanaka Y, Sekiguchi Y, Inamura Y, Sagawa Y, Mizukami A, Azegami K, Iwai S, Hachiya H, Ono Y, Takahashi A, Sasaki T, Yamauchi Y, Okada H, Suzuki A, Suzuki M, Handa K, Hirao K, Nakajima J, Nishimura T, Tao S, Takigawa M, Sasano T. Taomoto Y, et al. Among authors: sasaki t. J Arrhythm. 2025 Jan 14;41(1):e13182. doi: 10.1002/joa3.13182. eCollection 2025 Feb. J Arrhythm. 2025. PMID: 39817001 Free PMC article.
9,394 results